NCT06418594View on ClinicalTrials.gov

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2026

Conditions
HER2-negative Breast Cancer Brain Metastases
Interventions
DRUG

Adebrelimab

Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days

DRUG

Apatinib

Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days

DRUG

Etoposide

Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days

Trial Locations (1)

100071

RECRUITING

The Fifth Medical Center of PLA General Hospital, Beijing

All Listed Sponsors
lead

Beijing 302 Hospital

OTHER